Two educational programs are scheduled on Wednesday, September 29. The two programs will be be very different: one for very early stage patients; the other for patients with progressive prostate cancer at risk for (or already diagnosed with) de novo metastatic, hormone-sensitive prostate cancer (mHSPC) The earlier program that evening is being coordinated by the…
February 5, 2021 Multiparametric MRI-targeted biopsy for clinically significant prostate cancer can yield detection rates similar to systematic transrectal ultrasound-guided (TRUS) biopsy, while potentially enabling over one-third of prostate biopsies to be avoided, according to research published online February 4 in
In a multicenter, prospective, and randomized phase III study called PRostate Evaluation for Clinically Important Disease: MRI vs. Standard Evaluation Procedures (PRECISE), a team of researchers from Canada found that providing targeted biopsies after a positive multiparametric MRI scan was noninferior to systematic TRUS biopsies for detecting prostate cancers with an International Society of Urological Pathology grade group (GG) of 2 or higher.
(1)
UPPSALA, SWEDEN - LIDDS AB (publ) announces that a scientific article will be published in the highly ranked European Urology Focus describing LIDDS clinical Phase IIb study, LPC-004, and its clinical results. The study met both primary and secondary endpoints by confirming efficacy and safety with Liproca Depot given as intraprostatic injection in low- and intermediate risk prostate cancer patients. We are pleased that this manuscript is accepted in a highly recognized scientific paper and the results further validates NanoZolid as being an innovative technology platform, said Monica Wallter, CEO of LIDDS.
Liproca Depot, which comprises the NanoZolid technology combined with an antiandrogen drug (2-hydroxyflutamide) injected into the prostate, met both the primary and secondary endpoints in the study. Efficacy was shown by a maintained PSA decrease over 6 months, lower prostate volume and unchanged or improved MRI results. No hormonal side effects were shown. LIDDS conclud
email article
Prostate MRI followed by selective biopsy detected as many clinically significant cancers as standard ultrasound-guided systematic biopsy and detected 50% fewer low-risk cancers, a large randomized trial showed.
Targeted biopsy with multiparametric MRI identified grade group (GG) ≥2 tumors in 35% of men as compared with 30% for systematic biopsy with transrectal ultrasound (TRUS) guidance. The proportion of GG1 tumors decreased from 22% with TRUS biopsy (Bx) to 10% with targeted MRI-guided biopsy. Almost 40% of men randomized to the MRI group had negative imaging results, allowing them to avoid biopsy altogether.
Men who had MRI-guided prostate biopsy also had fewer adverse events (AEs), Laurence Klotz, MD, of the Sunnybrook Health Sciences Center in Toronto, and coauthors reported in
LIDDS AB
European Urology Focus has accepted a scientific article describing LIDDS Phase IIb study results with Liproca® Depot
European Urology Focus has accepted a scientific article describing LIDDS Phase IIb study results with Liproca® Depot
UPPSALA, SWEDEN – LIDDS AB (publ) announces that a scientific article will be published in the highly ranked European Urology Focus describing LIDDS clinical Phase IIb study, LPC-004, and its clinical results. The study met both primary and secondary endpoints by confirming efficacy and safety with Liproca Depot given as intraprostatic injection in low- and intermediate risk prostate cancer patients.
“We are pleased that this manuscript is accepted in a highly recognized scientific paper and the results further validates NanoZolid® as being an innovative technology platform,” said Monica Wallter, CEO of LIDDS.